Related Experiment Video
Updated: Jul 18, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
Druggable signaling proteins
Mouldy Sioud1, Marianne Leirdal
1Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Abstract:
In normal cells, signaling pathways are tightly regulated. However, when they are aberrantly activated, certain pathways are capable of causing diseases. In many tumors, the aberrantly activated signaling proteins include members of the epidermal growth factor receptor family, the Ras proteins, protein kinase C isoenzymes, BCR-ABL fusion protein as well as transcription factors such as signal transducers and activators of transcriptions and Myc. Accordingly, deregulation of these signaling proteins holds promise for the development of new anticancer drugs. Studies in vitro and in disease-relevant models demonstrated that blocking the activation of a key target in a constitutively activated signaling pathway could reverse disease phenotype. Moreover, constitutive activation of the target alone is sufficient to induce relevant disease phenotype. Notably, the most dramatic therapeutic advances in cancer therapy during the last decade have come from agents targeted against active thyrosine kinases. These include imatinib (anti-BCR-ABL), gefitinib (anti-EGF receptor), and herpetin (anti-ErbB-2). Here, some selected validated and drugable targets are summarized.
Insights
Aberrantly activated signaling pathways drive cancer. Targeting key proteins like tyrosine kinases offers a promising strategy for developing effective anticancer drugs by reversing disease phenotypes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cellular signaling pathways are crucial for normal function but aberrant activation can lead to diseases like cancer.
- Key signaling proteins frequently deregulated in tumors include epidermal growth factor receptor family, Ras proteins, and BCR-ABL fusion protein.
Purpose of the Study:
- To summarize validated and druggable targets in aberrant signaling pathways implicated in cancer.
- To highlight the therapeutic potential of targeting these activated signaling proteins for anticancer drug development.
Main Methods:
- Review of in vitro and in vivo studies demonstrating the effects of blocking key signaling targets.
- Analysis of therapeutic advances in cancer therapy focusing on targeted agents.
Main Results:
- Blocking key targets in constitutively activated signaling pathways can reverse disease phenotypes.
- Constitutive activation of specific targets is sufficient to induce disease phenotypes.
- Targeted therapies against active tyrosine kinases, such as imatinib and gefitinib, have shown significant success.
Conclusions:
- Deregulation of specific signaling proteins is a hallmark of cancer, presenting opportunities for targeted therapies.
- Targeting activated signaling pathways, particularly tyrosine kinases, represents a successful strategy in modern cancer treatment.
More Related Videos
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Signal Transduction: Overview
Typically, signal transduction involves three...
Amplifying Signals via Second Messengers
Types of Signaling Molecules